Description
The abstract establishes that Aβ and tau have synergistic effects rather than acting independently, but the precise molecular mechanisms driving this interaction remain unexplained. Understanding these mechanisms is crucial for developing combination therapies that target both pathologies simultaneously.
Gap type: unexplained_observation Source paper: Synergy between amyloid-β and tau in Alzheimer’s disease. (2020, Nature neuroscience, PMID:32778792)
Resolution criteria
Resolution requires: (1) Co-incubation experiments: Abeta oligomers plus tau aggregates applied to primary neurons or iPSC-derived neurons show >=50% greater synaptotoxicity (LDH release, dendritic spine loss, synaptic protein degradation) than either alone at equitoxic concentrations, identifying synergistic interaction (interaction term p<0.01 by two-way ANOVA); (2) Mechanistic dissection: co-immunoprecipitation, FRET, or BioID identifies >=1 shared mediator (e.g., Fyn kinase, PSD-95, NMDAR) required for synergy, with genetic or pharmacological disruption of the mediator abolishing the synergistic excess toxicity (>=70% reduction in synergy index); (3) In vivo validation in bigenic AD mouse model (APP/PS1 x PS19 tau) vs. single transgene: comparison of synaptic density (synaptophysin immunohistochemistry) confirms >=30% greater loss in bigenic animals, reversed by mediator-targeting compound. Additive rather than synergistic interaction models without mediator identification are insufficient.